Although we have not directly looked at safety in this study, a previous study by Stikvoort et al., 2021 [48] looked at the safety and efficacy of a modified KHYG-1 cell, a CD38-specific Chimeric Antigen Receptor Expressing KHYG-1 cell via retroviral transduction, in the context of multiple myeloma (MM). This evidence concerns the gene CD38 and plasma cell myeloma.